Skip to content

Study · Randomized controlled trial · n = 14 · 1987

8 results

Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.

Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A

Thrombosis and haemostasis1 Dec 1987Cited by 25 (Europe PMC)

PMID3127916 (opens in a new tab)PepBankPUB-03127916
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In hemophilic volunteers, intravenous DDAVP produced higher peak DDAVP levels than subcutaneous DDAVP (p less than 0.02).

    In plain wordsIn hemophilic volunteers, intravenous DDAVP produced higher peak drug levels than subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    IncreaseCmax
    Study

    n = 14

    Comparator
    Subcutaneous DDAVP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 micrograms/Kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Peak DDAVP levels (Cmax) were higher for i.v. DDAVP (p less than 0.02), times to peak levels (tmax) were shorter for i.v. DDAVP (p less than 0.001).
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In hemophilic volunteers, intravenous DDAVP had a shorter time to peak level than subcutaneous DDAVP (p less than 0.001).

    In plain wordsIn hemophilic volunteers, intravenous DDAVP reached its peak level sooner than subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    DecreaseTmax
    Study

    n = 14

    Comparator
    Subcutaneous DDAVP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 micrograms/Kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Peak DDAVP levels (Cmax) were higher for i.v. DDAVP (p less than 0.02), times to peak levels (tmax) were shorter for i.v. DDAVP (p less than 0.001).
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In hemophilic volunteers, DDAVP AUC did not differ between intravenous and subcutaneous administration.

    In plain wordsIn hemophilic volunteers, total DDAVP exposure did not differ between intravenous and subcutaneous administration.

    Peptide
    Desmopressin
    Outcome
    No significant changeAUC
    Study

    n = 14

    Comparator
    Intravenous versus subcutaneous DDAVP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 micrograms/Kg · intravenous and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the i.v. and s.c. routes for plasma DDAVP time curve (AUC) and half-life (t 1/2), but there was much larger variability for pharmacokinetic parameters with i.v. than with s.c. DDAVP.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In hemophilic volunteers, DDAVP half-life did not differ between intravenous and subcutaneous administration.

    In plain wordsIn hemophilic volunteers, DDAVP half-life did not differ between intravenous and subcutaneous administration.

    Peptide
    Desmopressin
    Outcome
    No significant changeHalf-life
    Study

    n = 14

    Comparator
    Intravenous versus subcutaneous DDAVP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 micrograms/Kg · intravenous and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the i.v. and s.c. routes for plasma DDAVP time curve (AUC) and half-life (t 1/2), but there was much larger variability for pharmacokinetic parameters with i.v. than with s.c. DDAVP.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In hemophilic volunteers, pharmacokinetic variability was much larger with intravenous than subcutaneous DDAVP.

    In plain wordsIn hemophilic volunteers, drug behavior varied more with intravenous than subcutaneous DDAVP.

    Peptide
    Desmopressin
    Outcome
    IncreasePharmacokinetic variability
    Study

    n = 14

    Comparator
    Subcutaneous DDAVP
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 micrograms/Kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was no difference between the i.v. and s.c. routes for plasma DDAVP time curve (AUC) and half-life (t 1/2), but there was much larger variability for pharmacokinetic parameters with i.v. than with s.c. DDAVP.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  6. 06HumanRandomized controlled trialMechanism

    In hemophilic volunteers, peak VIII:C did not correlate significantly with DDAVP levels for either administration route.

    In plain wordsIn hemophilic volunteers, peak clotting factor VIII activity did not correlate significantly with DDAVP levels for either route.

    Peptide
    Desmopressin
    Outcome
    No significant changePeak VIII:C correlation with DDAVP levels
    Study

    n = 14

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 micrograms/Kg · intravenous and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Post-DDAVP VIII:C increased 3.4 +/- 1.6 fold (i.v.) and 3.3 +/- 1.3 fold (s.c.) over baseline levels, with no significant correlation between peak VIII:C and DDAVP levels for either route of administration.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  7. 07HumanNon-randomized trialMechanism

    In hemophilic volunteers, intravenous DDAVP increased VIII:C 3.4 +/- 1.6 fold over baseline.

    In plain wordsIn hemophilic volunteers, intravenous DDAVP increased clotting factor VIII activity compared with baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseVIII:C response intravenously
    Study

    n = 14

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 micrograms/Kg · intravenousAs given in this study (human).

    Measurements

    VIII:C fold increase over baseline, mean
    3.4 fold
    intravenous DDAVP
    VIII:C fold increase over baseline, SD
    1.6 fold
    intravenous DDAVP

    Source sentences

    Summary
    Post-DDAVP VIII:C increased 3.4 +/- 1.6 fold (i.v.) and 3.3 +/- 1.3 fold (s.c.) over baseline levels, with no significant correlation between peak VIII:C and DDAVP levels for either route of administration.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.
  8. 08HumanNon-randomized trialMechanism

    In hemophilic volunteers, subcutaneous DDAVP increased VIII:C 3.3 +/- 1.3 fold over baseline.

    In plain wordsIn hemophilic volunteers, subcutaneous DDAVP increased clotting factor VIII activity compared with baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseVIII:C response subcutaneously
    Study

    n = 14

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 micrograms/Kg · subcutaneousAs given in this study (human).

    Measurements

    VIII:C fold increase over baseline, mean
    3.3 fold
    subcutaneous DDAVP
    VIII:C fold increase over baseline, SD
    1.3 fold
    subcutaneous DDAVP

    Source sentences

    Summary
    Post-DDAVP VIII:C increased 3.4 +/- 1.6 fold (i.v.) and 3.3 +/- 1.3 fold (s.c.) over baseline levels, with no significant correlation between peak VIII:C and DDAVP levels for either route of administration.
    1 context sentence
    Summary · context
    To evaluate whether or not between-patient variability is related to DDAVP levels achieved in plasma, we measured drug levels in 14 hemophilic volunteers (VIII:C 2 to 31 U/dL) who were randomly given 0.3 micrograms/Kg of i.v. or s.c. DDAVP and crossed-over to the other treatment after an interval of 15-30 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT06020456

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A

Groupe Maladies hémorragiques de Bretagnen = 3611 Jan 2022 to 1 Apr 2023

Carrier of Hemophilia A · Desmopressin · Factor VIII Deficiency

Trial pageClinicalTrials.govUpdated 31 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.